Compass Pathways PLC
CMPS6.680USD
-0.165-2.41%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
641.29MMarket Cap
LossP/E TTM
More Details of Compass Pathways PLC Company
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Compass Pathways PLC Info
Ticker SymbolCMPS
Company nameCompass Pathways PLC
IPO dateSep 18, 2020
CEONath (Kabir)
Number of employees166
Security typeDepository Receipt
Fiscal year-endSep 18
Address3Rd Floor, 1 Ashley Road
CityALTRINCHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeWA14 2DT
Phone17166766461
Websitehttps://compasspathways.com/
Ticker SymbolCMPS
IPO dateSep 18, 2020
CEONath (Kabir)
Company Executives of Compass Pathways PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Robert McQuade, Ph.D.
Dr. Robert McQuade, Ph.D.
Independent Director
Independent Director
1.59M
--
Mr. Thomas Lonngren
Mr. Thomas Lonngren
Independent Director
Independent Director
89.05K
--
Mr. Kabir Nath
Mr. Kabir Nath
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
29.07K
+944.11%
Mr. David Norton
Mr. David Norton
Independent Director
Independent Director
20.36K
+17.06%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Director
Independent Director
19.48K
+17.97%
Ms. Teri Loxam
Ms. Teri Loxam
Chief Financial Officer
Chief Financial Officer
11.21K
-86.53%
Dr. Guy Goodwin
Dr. Guy Goodwin
Chief Medical Officer
Chief Medical Officer
1.99K
--
Mr. Justin Gover
Mr. Justin Gover
Director
Director
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Wayne Joseph Riley, M.D.
Dr. Wayne Joseph Riley, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Robert McQuade, Ph.D.
Dr. Robert McQuade, Ph.D.
Independent Director
Independent Director
1.59M
--
Mr. Thomas Lonngren
Mr. Thomas Lonngren
Independent Director
Independent Director
89.05K
--
Mr. Kabir Nath
Mr. Kabir Nath
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
29.07K
+944.11%
Mr. David Norton
Mr. David Norton
Independent Director
Independent Director
20.36K
+17.06%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Director
Independent Director
19.48K
+17.97%
Ms. Teri Loxam
Ms. Teri Loxam
Chief Financial Officer
Chief Financial Officer
11.21K
-86.53%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
9.07%
Deep Track Capital LP
8.19%
Atai Life Sciences AG
6.03%
GMT Capital Corp.
2.96%
Millennium Management LLC
2.83%
Other
70.93%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
9.07%
Deep Track Capital LP
8.19%
Atai Life Sciences AG
6.03%
GMT Capital Corp.
2.96%
Millennium Management LLC
2.83%
Other
70.93%
Shareholder Types
Shareholders
Proportion
Hedge Fund
27.73%
Investment Advisor/Hedge Fund
15.31%
Investment Advisor
11.88%
Individual Investor
6.10%
Corporation
6.03%
Research Firm
4.24%
Bank and Trust
1.63%
Venture Capital
0.68%
Endowment Fund
0.22%
Other
26.18%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
283
57.38M
72.50%
+6.72K
2025Q3
301
57.46M
74.76%
+3.34M
2025Q2
285
53.63M
67.49%
+1.03M
2025Q1
275
52.65M
51.90%
+4.46M
2024Q4
270
31.64M
55.25%
-1.83M
2024Q3
260
33.66M
49.30%
+4.32M
2024Q2
262
29.34M
47.25%
+403.49K
2024Q1
263
28.00M
40.12%
+578.36K
2023Q4
271
23.51M
40.32%
+723.33K
2023Q3
272
22.78M
29.97%
+8.57M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
8.22M
8.57%
+2.68M
+48.46%
Jun 30, 2025
Deep Track Capital LP
8.83M
9.2%
-28.64K
-0.32%
Jun 30, 2025
Atai Life Sciences AG
6.91M
7.2%
--
--
Mar 05, 2025
GMT Capital Corp.
1.78M
1.86%
--
--
Jun 30, 2025
Millennium Management LLC
1.74M
1.82%
-1.03M
-37.20%
Jun 30, 2025
Tang Capital Management, LLC
1.30M
1.35%
-100.00K
-7.14%
Jun 30, 2025
ARK Investment Management LLC
1.65M
1.72%
-155.58K
-8.62%
Jun 30, 2025
Goldsmith (George Jay)
2.05M
2.14%
-129.33K
-5.93%
Mar 31, 2025
Malievskaia (Ekaterina)
2.03M
2.11%
-149.38K
-6.86%
Mar 31, 2025
UBS Financial Services, Inc.
1.40M
1.46%
+402.30K
+40.20%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
8.41%
Simplify Propel Opportunities ETF
2.71%
ARK Genomic Revolution ETF
1.23%
Virtus LifeSci Biotech Clinical Trials ETF
0.95%
ALPS Medical Breakthroughs ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
SPDR S&P International Small Cap ETF
0.06%
iShares Biotechnology ETF
0.04%
Putnam Sustainable Future ETF
0%
View more
AdvisorShares Psychedelics ETF
Proportion8.41%
Simplify Propel Opportunities ETF
Proportion2.71%
ARK Genomic Revolution ETF
Proportion1.23%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.95%
ALPS Medical Breakthroughs ETF
Proportion0.24%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
SPDR S&P International Small Cap ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.04%
Putnam Sustainable Future ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Compass Pathways PLC?
The top five shareholders of Compass Pathways PLC are:
RTW Investments L.P. holds 8.22M shares, accounting for 8.57% of the total shares.
Deep Track Capital LP holds 8.83M shares, accounting for 9.20% of the total shares.
Atai Life Sciences AG holds 6.91M shares, accounting for 7.20% of the total shares.
GMT Capital Corp. holds 1.78M shares, accounting for 1.86% of the total shares.
Millennium Management LLC holds 1.74M shares, accounting for 1.82% of the total shares.
RTW Investments L.P. holds 8.22M shares, accounting for 8.57% of the total shares.
Deep Track Capital LP holds 8.83M shares, accounting for 9.20% of the total shares.
Atai Life Sciences AG holds 6.91M shares, accounting for 7.20% of the total shares.
GMT Capital Corp. holds 1.78M shares, accounting for 1.86% of the total shares.
Millennium Management LLC holds 1.74M shares, accounting for 1.82% of the total shares.
What are the top three shareholder types of Compass Pathways PLC?
The top three shareholder types of Compass Pathways PLC are:
RTW Investments L.P.
Deep Track Capital LP
Atai Life Sciences AG
RTW Investments L.P.
Deep Track Capital LP
Atai Life Sciences AG
How many institutions hold shares of Compass Pathways PLC (CMPS)?
As of 2025Q4, 283 institutions hold shares of Compass Pathways PLC, with a combined market value of approximately 57.38M, accounting for 72.50% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.26%.
What is the biggest source of revenue for Compass Pathways PLC?
In --, the -- business generated the highest revenue for Compass Pathways PLC, amounting to -- and accounting for --% of total revenue.
